Biopharma gains a seamless transition from drug discovery through drug product manufacturing
SAN DIEGO, June 20, 2024 /PRNewswire/ — Abzena, the leading end-to-end integrated contract and development manufacturing organization (CDMO) for complex biologics and bioconjugates, and Argonaut Manufacturing Services, Inc., a cGMP CDMO serving the biopharmaceutical and diagnostics industries, announced a strategic partnership to provide a fully integrated drug substance and drug product manufacturing solution for biopharmaceutical organizations. This alliance offers a streamlined approach for customers looking to rapidly progress therapies into the clinic, or onward into later-stage commercial manufacturing.
The partnership removes the white space in drug development for biopharma drug companies by utilizing a single development and manufacturing team to seamlessly transition from early discovery services (ranging from antibody engineering, developability, formulation development, cell line development, process and analytical development) through clinical and commercial manufacturing of drug substance and drug product. This tight integration of activities facilitates more informed and rapid decision-making, efficient technology transfer, and a reduction in supply chain complexity.
Both Abzena and Argonaut have extensive experience in developing and manufacturing biopharmaceutical programs that span the entire development pathway. By harmonizing Abzena’s comprehensive antibody discovery, development and cGMP manufacturing capabilities with Argonaut’s exemplary sterile fill-finish offering, encapsulates a full-spectrum service model designed to optimize efficiency and accelerate development timelines.
Matt Stober, CEO of Abzena said, “Abzena’s mission is to rapidly move medicines forward to patients in need. Embarking on this strategic partnership with Argonaut further demonstrates our commitment to this mission, marking a significant milestone in our quest to provide streamlined solutions that address the unique needs of our customers. This collaboration signifies a pivotal advancement in biopharmaceutical development and reinforces the shared vision of both our organizations to drive innovation, quality, and speed to market for our customer’s life-changing treatments.
Wayne Woodard, CEO of Argonaut said, “For the past few years, Argonaut and Abzena have been successfully building and strengthening their partnership. Today, we further enhance this collaboration by publicly recognizing the value that our two companies can generate for our clients. Ecosystems are an integral part of our business, and these partnerships are crucial in providing comprehensive support to all our clients, regardless of their size, to ensure efficient and successful delivery of their drugs to patients.”
About Abzena
Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule and move medicines forward faster. The company has research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK. Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors.
About Argonaut Manufacturing Services, Inc.
Argonaut Manufacturing Services, Inc. is an FDA-registered cGMP contract manufacturing organization (CMO) dedicated to providing custom manufacturing and supply chain solutions for biopharmaceutical and diagnostic companies. Aseptic drug fill/finish features state-of-the-art automated equipment for high-yield filling of sterile injectable drugs including biologics, peptides, small molecules, and vaccines. Diagnostic manufacturing includes proprietary lyophilization technology and a spectrum of kitting capabilities. Projects are supported with full analytical quality control services including warehousing and global shipping logistics. Serving innovators in the life science, molecular diagnostics, and biopharma industries, Argonaut provides a wide range of flexible solutions for diverse outsourcing needs.
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Skyline Therapeutics Receives FDA Orphan Drug Designation for Gene Therapy for Retinitis Pigmentosa
BOSTON & SHANGHAI, September 2, 2024 – Skyline Therapeutics, a gene therapy company focused on innovative treatments for rare and severe diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SKG1108....
Novavax Receives Emergency Use Authorization for Updated Covid-19 Vaccine
Novavax has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its updated Covid-19 vaccine, NVX-CoV2705, joining other vaccine manufacturers in addressing evolving virus variants. The EUA permits the use of Novavax's...
Turn Biotechnologies Reports Historic Skin Cell Rejuvenation Breakthroughs at ESDR this Week
Company will present data from its successful rejuvenation of fibroblasts and keratinocytes to influential gathering of international dermatologists MOUNTAIN VIEW, Calif., Sept. 4, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and...
H5 influenza vaccines: What needs to be done to reduce the risk of a pandemic
As the global threat of H5N1 influenza looms with outbreaks across species and continents including the U.S., three international vaccine and public health experts say it is time to fully resource and support a robust strategy to address this and future potential...
Related Services
Plasmids GMP Services
AAV GMP Services
